Therefore, we suggest that, in future trials, dual TIM-3 and PD-1/PD-L1 inhibition should be considered for patients with CMS4 and MSI CRC, where TIM-3 is highly expressed in the TGFβ-rich TME. Here, TGFB1 is linked to colorectal carcinoma.